संयुक्त राज्य - अंग्रेज़ी - NLM (National Library of Medicine)

deseret biologicals, inc. - human parvovirus b19 (unii: 94n635564t) (human parvovirus b19 - unii:94n635564t) - human parvovirus b19 15 in 1 ml - for the temporary relief of symptoms related to parvovirus including rash, swollen, painful joints and fever.** **these statements are based upon traditional homeopathic principles. they have not been reviewed by the food and drug administration. for the temporary relief of symptoms related to parvovirus including rash, swollen, painful joints and fever.** **these statements are based upon traditional homeopathic principles. they have not been reviewed by the food and drug administration.

संयुक्त राज्य - अंग्रेज़ी - NLM (National Library of Medicine)

deseret biologicals, inc - human parvovirus b19 (unii: 94n635564t) (human parvovirus b19 - unii:94n635564t) - human parvovirus b19 15 [hp_x] in 1 ml - for the temporary relief of symptoms related to parvovirus including rash, swollen, painful joints and fever.** **these statements are based upon traditional homeopathic practice. they have not been reviewed by the food and drug administration. for the temporary relief of symptoms related to parvovirus including rash, swollen, painful joints and fever.** **these statements are based upon traditional homeopathic practice. they have not been reviewed by the food and drug administration.

संयुक्त राज्य - अंग्रेज़ी - NLM (National Library of Medicine)

apotheca company - human parvovirus b19 (unii: 94n635564t) (human parvovirus b19 - unii:94n635564t) - human parvovirus b19 15 [hp_x] in 1 ml -     indications:  for the temporary relief of symptoms related to parvovirus including rash, swollen, painful joints and fever. indications:   for the temporary relief of symptoms related to parvovirus including rash, swollen, painful joints and fever.

सऊदी अरब - अंग्रेज़ी - SFDA (Saudi Food and Drug Authority)- الهيئة العامة للغذاء والدواء

human bioplazma llc, hungary - albumin human - solution - 20 %

सऊदी अरब - अंग्रेज़ी - SFDA (Saudi Food and Drug Authority)- الهيئة العامة للغذاء والدواء

human bioplazma llc, hungary - albumin human - solution - 20 %

माल्टा - अंग्रेज़ी - Medicines Authority

central procurement & supplies unit ub002 industrial estate, san gwann sgn 3000, malta - human hepatitis, b immunoglobulin, human plasma, protein - solution for injection - human hepatitis b immunoglobulin 200 iu human plasma protein 100-170 mg - immune sera and immunoglobulins

केन्या - अंग्रेज़ी - Pharmacy and Poisons Board

human albumin 20% - infusion - human albumin 20% - albumin

ऑस्ट्रेलिया - अंग्रेज़ी - Department of Health (Therapeutic Goods Administration)

csl behring australia pty ltd - tetanus immunoglobulin, quantity: 250 iu; human immunoglobulin g, quantity: 160 mg/ml - injection, solution - excipient ingredients: glycine; human immunoglobulin a - tetanus immunoglobulin is indicated for the passive protection of individuals who have sustained a tetanus-prone wound and who have either not been actively immunised against tetanus or whose immunisation history is doubtful. it should also be given to the fully immunised patient with a tetanus-prone wound if more than 10 years have elapsed since the last dose of toxoid. in all the above instances, active immunisation with tetanus toxoid, adsorbed or adt vaccine should be commenced at the same time [in accordance with details specified in table 1 (guide to tetanus prophylaxis in wound management) in indication section of the approved product information provided as attachment 1]. although tetanus immunoglobulin and vaccine should be given at the same time, they should be administered in opposite limbs, using separate syringes.

ऑस्ट्रेलिया - अंग्रेज़ी - Department of Health (Therapeutic Goods Administration)

merck sharp & dohme (australia) pty ltd - hepatitis b surface antigen recombinant, quantity: 10 microgram/ml - injection, suspension - excipient ingredients: aluminium; borax; sodium chloride; water for injections - h-b-vax ii is indicated for immunisation against infection caused by all known subtypes of hepatitis b virus. adolescent vaccination is not necessary for children who have received a primary course of hepatitis b vaccine. vaccination is recommended in adults who ar at substantial risk of hepatitis b virus infection and have demonstrated or judged to be susceptible. vaccination of individuals who have antibodies against hepatitis b virus from a previous infection is not necessary.

ऑस्ट्रेलिया - अंग्रेज़ी - Department of Health (Therapeutic Goods Administration)

merck sharp & dohme (australia) pty ltd - hepatitis b surface antigen recombinant, quantity: 5 microgram - injection, suspension - excipient ingredients: borax; water for injections; sodium chloride; aluminium - for use in the immunisation against infection caused by all known subtypes of hepatitis b virus. indications as at 17 november 2000: h-b-vax ii is indicated for immunisation against infection caused by all known subtypes of hepatitis b virus. adolescent vaccination is not necessary for children who have received a primary course of hepatitis b vaccine. vaccination is recommended in adults who are at substantial risk of hepatitis b virus infection and have demonstrated or judged to be susceptible. vaccination of individuals who have antibodies against hepatitis b virus from a previous infection is not necessary.